ARTICLE | Company News
Gilead boosts foothold in cell therapy with new facilities
May 15, 2018 7:30 PM UTC
The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) said Tuesday it has leased a new facility in Hoofddorp, the Netherlands to engineer cell therapies, including Yescarta axicabtagene ciloleucel, for patients in Europe. An MAA for Yescarta is under EMA review.
The facility is expected to be fully operational in 2020...